Microbiome Therapy

Who would have thought that microbiome targeted therapies would have become such a major focus in drug development? With multiple microbiome-based candidates in early-phase pre-clinical and clinical development, there is a growing demand for manufacturing capacity suitable for the production of live biotherapeutic products (LBP’s). The importance of appropriately designed facilities to ensure effective conditions for scale-up and manufacture of these LPBs cannot be underestimated as part of an overall market access strategy.

DPS has been privileged to work with companies developing these live biotherapeutic products and can support your teams with their manufacturing facility feasibility planning and execution, call us today.

 

 

Back to top
DPS Group addresses the COVID-19 pandemic:
A message from Frank Keogh, CEO

Find out more Contact Us